Selenoprotein P as a diabetes-associated hepatokine that impairs angiogenesis by inducing VEGF resistance in vascular endothelial cells

Diabetologia

Volumn 57, Issue 9, 2014, Pages 1968-1976

  Ishikura, Kazuhide ^a   Misu, Hirofumi ^a   Kumazaki, Masafumi ^a,b   Takayama, Hiroaki ^a   Matsuzawa Nagata, Naoto ^a   Tajima, Natsumi ^a   Chikamoto, Keita ^a   Lan, Fei ^a   Ando, Hitoshi ^a,b   Ota, Tsuguhito ^a   Sakurai, Masaru ^a,c   Takeshita, Yumie ^a   Kato, Kenichiro ^a   Fujimura, Akio ^b   Miyamoto, Ken Ichi ^a   Saito, Yoshiro ^d   Kameo, Satomi ^e   Okamoto, Yasuo ^a   Takuwa, Yoh ^a   Takahashi, Kazuhiko ^f   Kidoya, Hiroyasu ^g   Takakura, Nobuyuki ^g   Kaneko, Shuichi ^a   Takamura, Toshinari ^a   more..

^a KANAZAWA UNIVERSITY   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c KANAZAWA MEDICAL UNIVERSITY   (Japan)

^d DOSHISHA UNIVERSITY   (Japan)

^e GUNMA UNIVERSITY   (Japan)

^f HOKKAIDO INSTITUTE OF TECHNOLOGY   (Japan)

^g OSAKA UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Hepatokine; ROS; Selenoprotein P; VEGF

Indexed keywords

BUTHIONINE SULFOXIMINE; CYTOKINE; GLUCOSE; HEPATOKINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; REACTIVE OXYGEN METABOLITE; SELENOPROTEIN P; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN A; CD31 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD FLOW; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIUM CELL; GENE; GENE DELETION; GENE OVEREXPRESSION; INSULIN RESISTANCE; LEG ISCHEMIA; LIVER CELL; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEPP1 GENE; SIGNAL TRANSDUCTION; WOUND CLOSURE; WOUND HEALING; ANIMAL; GENETICS; KNOCKOUT MOUSE; METABOLISM; MUTANT MOUSE STRAIN; PHYSIOLOGY; PROMOTER REGION; UMBILICAL VEIN ENDOTHELIAL CELL; GLUTATHIONE METABOLISM; HUMAN; PROTEIN PURIFICATION;

ANIMALS; CELL PROLIFERATION; DIABETES MELLITUS, TYPE 2; ENDOTHELIAL CELLS; GLUCOSE; HEPATOCYTES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; MICE; MICE, KNOCKOUT; MICE, MUTANT STRAINS; PROMOTER REGIONS, GENETIC; SELENOPROTEIN P; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 84905563432     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3306-9     Document Type: Article

References (42)

1. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577-1589
2. Gerstein HC, Miller ME, Byington RP, et al. (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545-2559
3. Simons M (2005) Angiogenesis, arteriogenesis, and diabetes: paradigm reassessed? J Am Coll Cardiol 46:835-837
4. Abaci A, Oguzhan A, Kahraman S, et al. (1999) Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 99:2239-2242
5. Yarom R, Zirkin H, Stammler G, Rose AG (1992) Human coronary microvessels in diabetes and ischaemia. Morphometric study of autopsy material. J Pathol 166:265-270
6. Al-Delaimy WK, Merchant AT, Rimm EB, Willett WC, Stampfer MJ, Hu FB (2004) Effect of type 2 diabetes and its duration on the risk of peripheral arterial disease among men. Am J Med 116:236-240
7. Hueb W, Gersh BJ, Costa F, et al. (2007) Impact of diabetes on five-year outcomes of patients with multivessel coronary artery disease. Ann Thorac Surg 83:93-99
8. Galiano RD, Tepper OM, Pelo CR, et al. (2004) Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am J Pathol 164:1935-1947
9. Boodhwani M, Sellke FW (2009) Therapeutic angiogenesis in diabetes and hypercholesterolemia: influence of oxidative stress. Antioxid Redox Signal 11:1945-1959
10. Jude EB, Eleftheriadou I, Tentolouris N (2010) Peripheral arterial disease in diabetes-a review. Diabet Med 27:4-14
11. Waltenberger J (2009) VEGF resistance as a molecular basis to explain the angiogenesis paradox in diabetes mellitus. Biochem Soc Trans 37:1167-1170
12. Carlson BA, Novoselov SV, Kumaraswamy E, et al. (2004) Specific excision of the selenocysteine tRNA[Ser]Sec (Trsp) gene in mouse liver demonstrates an essential role of selenoproteins in liver function. J Biol Chem 279:8011-8017
13. Burk RF, Hill KE (2005) Selenoprotein P: an extracellular protein with unique physical characteristics and a role in selenium homeostasis. Annu Rev Nutr 25:215-235
14. Saito Y, Takahashi K (2002) Characterization of selenoprotein P as a selenium supply protein. Eur J Biochem/FEBS 269:5746-5751
15. Misu H, Takamura T, Takayama H, et al. (2010) A liver-derived secretory protein, selenoprotein P, causes insulin resistance. Cell Metab 12:483-495
16. Yang SJ, Hwang SY, Choi HY, et al. (2011) Serum selenoprotein P levels in patients with type 2 diabetes and prediabetes: implications for insulin resistance, inflammation, and atherosclerosis. J Clin Endocrinol Metab 96:E1325-E1329
17. Arteel GE, Franken S, Kappler J, Sies H (2000) Binding of selenoprotein P to heparin: characterization with surface plasmon resonance. Biol Chem 381:265-268
18. Burk RF, Hill KE, Boeglin ME, Ebner FF, Chittum HS (1997) Selenoprotein P associates with endothelial cells in rat tissues. Histochem Cell Biol 108:11-15
19. Steinbrenner H, Bilgic E, Alili L, Sies H, Brenneisen P (2006) Selenoprotein P protects endothelial cells from oxidative damage by stimulation of glutathione peroxidase expression and activity. Free Radic Res 40:936-943
20. Takayama H, Misu H, Iwama H, et al. (2013) Metformin suppresses expression of the selenoprotein P gene via an AMPK-FoxO3a pathway in H4IIEC3 hepatocytes. J Biol Chem
21. Hill KE, Zhou J, McMahan WJ, et al. (2003) Deletion of selenoprotein P alters distribution of selenium in the mouse. J Biol Chem 278:13640-13646
22. Watkinson JH (1966) Fluorometric determination of selenium in biological material with 2,3-diaminonaphthalene. Anal Chem 38:92-97
23. Abdulah R, Miyazaki K, Nakazawa M, Koyama H (2005) Low contribution of rice and vegetables to the daily intake of selenium in Japan. Int J Food Sci Nutr 56:463-471
24. Saito Y, Hayashi T, Tanaka A, et al. (1999) Selenoprotein P in human plasma as an extracellular phospholipid hydroperoxide glutathione peroxidase. Isolation and enzymatic characterization of human selenoprotein p. J Biol Chem 274:2866-2871
25. Saito Y, Watanabe Y, Saito E, Honjoh T, Takahashi K (2001) Production and application of monoclonal antibodies to human selenoprotein P. J Health Sci 47:346-352
26. Luttun A, Tjwa M, Moons L, et al. (2002) Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 8:831-840
27. Ushio-Fukai M (2007) VEGF signaling through NADPH oxidase-derived ROS. Antioxid Redox Signal 9:731-739
28. Waltenberger J, Lange J, Kranz A (2000) Vascular endothelial growth factor-A-induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus: a potential predictor for the individual capacity to develop collaterals. Circulation 102:185-190
29. Tchaikovski V, Olieslagers S, Bohmer FD, Waltenberger J (2009) Diabetes mellitus activates signal transduction pathways resulting in vascular endothelial growth factor resistance of human monocytes. Circulation 120:150-159
30. Sasso FC, Torella D, Carbonara O, et al. (2005) Increased vascular endothelial growth factor expression but impaired vascular endothelial growth factor receptor signaling in the myocardium of type 2 diabetic patients with chronic coronary heart disease. J Am Coll Cardiol 46:827-834
31. Misu H, Takamura T, Matsuzawa N, et al. (2007) Genes involved in oxidative phosphorylation are coordinately upregulated with fasting hyperglycaemia in livers of patients with type 2 diabetes. Diabetologia 50:268-277
32. Takamura T, Sakurai M, Ota T, Ando H, Honda M, Kaneko S (2004) Genes for systemic vascular complications are differentially expressed in the livers of type 2 diabetic patients. Diabetologia 47:638-647
33. Takamura T, Misu H, Matsuzawa-Nagata N, et al. (2008) Obesity upregulates genes involved in oxidative phosphorylation in livers of diabetic patients. Obesity 16:2601-2609
34. Maulik N, Das DK (2002) Redox signaling in vascular angiogenesis. Free Radic Biol Med 33:1047-1060
35. Costa PZ, Soares R (2013) Neovascularization in diabetes and its complications. Unraveling the angiogenic paradox. Life Sci 92:1037-1045
36. Gupta N, Mansoor S, Sharma A, et al. (2013) Diabetic retinopathy and VEGF. Open Ophthalmol J 7:4-10
37. Nakagawa T, Kosugi T, Haneda M, Rivard CJ, Long DA (2009) Abnormal angiogenesis in diabetic nephropathy. Diabetes 58:1471-1478
38. Hagberg CE, Mehlem A, Falkevall A, et al. (2012) Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes. Nature 490:426-430
39. Patterson KI, Brummer T, O'Brien PM, Daly RJ (2009) Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J 418:475-489
40. Deagen JT, Beilstein MA, Whanger PD (1991) Chemical forms of selenium in selenium containing proteins from human plasma. J Inorg Biochem 41:261-268
41. Kurokawa S, Eriksson S, Rose KL, et al. (2014) Sepp1(UF) forms are N-terminal selenoprotein P truncations that have peroxidase activity when coupled with thioredoxin reductase-1. Free Radic Biol Med 69:67-76
42. Renko K, Hofmann PJ, Stoedter M, et al. (2009) Down-regulation of the hepatic selenoprotein biosynthesis machinery impairs selenium metabolism during the acute phase response in mice. FASEB J 23:1758-1765